Purpose: Proteomic analysis of breast nipple aspirate fluid (NAF) holds promise as a noninvasive method to identify markers of breast cancer. The objectives of the study were to: (a) describe the NAF proteome, (b) identify candidate markers of breast cancer in NAF by using proteomic analysis, and (c) validate the markers identified by using a quantitative, high-throughput ELISA analysis.
INTRODUCTION
Early detection is a major factor contributing to the 3.2% annual decline in breast cancer death rates over the past 5 years (1, 2). Unfortunately, currently available breast cancer screening tools such as mammography and breast examination miss up to 40% of early breast cancers and are least effective in detecting cancer in young women, whose tumors are often more aggressive. An invasive needle or surgical biopsy must be performed when an area of suspicion is identified to confirm, by cytologic or histologic evaluation, the presence of malignant disease. The development of noninvasive techniques that would distinguish between women with and women without breast cancer, as well as between different disease stages, is, therefore, of crucial importance.
Recent advances in comprehensive molecular technologies have allowed the analysis of global gene expression or protein profiles in cancerous versus normal tissues with the goal of identifying RNA or protein markers that are differentially expressed between benign and malignant tissues. One such study (3, 4) analyzed RNA by using serial analysis of gene expression to identify molecular alterations involved in breast cancer progression. The authors concluded that very few genes were up-regulated in all tumors, presumably reflecting the high degree of diversity among tumors at the molecular level. The most dramatic changes occurred at the transition from benign breast tissue to in situ carcinoma, in which many of the highly expressed genes encoded secreted proteins, mainly cytokines and chemokines, implicating abnormal paracrine and autocrine signaling in the initiation of breast cancer.
Other nucleic acid-based studies have examined samples of normal versus cancerous tissues, established cell lines, and samples from before and after treatment with chemotherapeutic agents for differences in expression of a set of Ͼ400 genes, by using hierarchical clustering to analyze the results (5, 6) . Although the authors report variation among different tumor samples, these studies have shown that cancers can be classified into subgroups based on patterns of gene expression, and that this classification may prove useful for prognosis.
Several proteomic studies have compared normal and cancerous breast cells [reviewed in detail by Hondermarck et al. (7) ]. A hierarchical clustering analysis of proteomes of normal and different stages of disease have shown that it is possible to distinguish between normal, benign, and cancerous breast tis-sues on the basis of the protein profile (8) . Page et al. (9) established an extensive map of the normal human luminal and basal (myoepithelial) breast cell proteome as the basis for future comparisons with breast cancer cells. The authors observed 170 differentially displayed protein spots, and identified 51 of them. A subsequent proteomic study of breast ductal carcinoma identified 57 proteins that were differentially expressed based on disease stage, 10 of which were validated by immunohistochemical studies (10) . Many were proteins involved in the regulation of intracellular trafficking, cytoskeletal architecture, chaperone function, apoptosis, and genome instability. In a more focused study, the molecular chaperone 14-3-3 was shown to be involved in the transition of breast epithelial cells to neoplasia. By virtue of its role as a tumor suppressor, it was suggested that 14-3-3 may be a useful marker to identify cells that have undergone this transition (11).
Interestingly, many proteins that have been identified by proteomic studies are different from those found by nucleic acid-based studies. This underscores the importance of performing biomarker screens at the protein level and suggests that many of the differences between normal and cancer samples are due to posttranslational modifications such as glycosylation or truncation (12) . However, although promising, proteomic analyses of breast tissues, to date, suffer from the fact that the tissues are not homogeneous and more than one cell type is likely to be present in the samples. For this reason some of the above studies were done on cells in culture, although the relevance of the in vitro physiology and biochemistry in these studies to that of the normal or diseased human breast is unclear. Many of the studies that use cells have found few proteins with substantial differential expression. Moreover, studies requiring a large cellular sample require an invasive procedure to obtain the samples for analysis.
Nipple aspiration is a noninvasive, low-cost procedure that provides a relatively small set of breast-specific proteins. Because the proteins are secreted, they represent the final processed form of the protein, which makes proteomic analyses less ambiguous and can provide clues to changes in protein translational rates, posttranslational modification, sequestration, and degradation that lead to disease. Validation of these noninvasive procedures requires the demonstration that biological markers in the fluid correlate with breast tissue pathology and, thus, predict disease. These markers may or may not have been previously identified in cells from breast cancer specimens.
Several studies indicate that nipple aspirate fluid (NAF) contains potentially diagnostic or prognostic markers of breast cancer. A study that used surface enhanced laser desorption ionization (SELDI) analysis identified five differentially expressed proteins in NAF from benign versus cancerous breasts (13) , although none of these proteins have been identified. Subsequent studies found that low levels of prostate-specific antigen (PSA) and high levels of insulin-like growth factor binding protein-3 (IGFBP-3) are associated with breast cancer (14) , and that high levels in NAF of urinary plasminogen activator (uPA) and its receptor, uPAR, significantly contributed to a model that predicted which women had breast cancer (15) .
In this study, we present (a) a partial description of the NAF proteome (41 protein identifications), (b) the identification of three candidate proteins by two-dimensional PAGE and matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) with different expression levels based on whether a subject did or did not have breast cancer, and (c) the subsequent validation of these differentially expressed proteins by using an ELISA on a large set of NAF specimens from women with and without breast cancer. Three candidate proteins: gross cystic disease fluid protein (GCDFP)-15 (also know as prolactin-induced protein or BRST2), lipoprotein D [apolipoprotein D (apoD)], and ␣1-acid glycoprotein (AAG), were differentially expressed in a small set of cancer versus benign samples analyzed by two-dimensional PAGE and subsequently examined by ELISA in a large set of NAF samples comparing women with or without breast cancer, as well as women with in situ (early stage) versus invasive (more advanced stage) disease. We demonstrate that the levels of GCDFP-15 are substantially lower and AAG are substantially higher in samples from women with breast cancer, whereas levels of apoD in NAF were not associated with disease. This stepwise approach to biomarker detection and validation suggests that proteomic analysis of bodily fluids such as NAF are appropriate for biomarker detection, can be readily validated by using high-throughput, quantitative technologies and may prove useful for early breast cancer detection and/or prognosis prediction.
MATERIALS AND METHODS
Subjects. NAF specimens from subjects, 17-83 years old, were collected after Institutional Review Board approval and informed consent were obtained. Some subjects had specimens analyzed from one breast only, whereas others had specimens analyzed from both breasts. The presence or absence of cancer was based on whether or not disease was present in a given breast. Fifty-three specimens were collected from 38 patients without evidence of cancer in the analyzed breast. The remaining 52 specimens were obtained from 51 subjects that had pathologically confirmed ductal carcinoma in situ (DCIS) or invasive breast cancer. For women with breast cancer, all of the specimens were collected before, or in conjunction with, definitive treatment. Ninety percent (94 of 105) of the samples were from Caucasian subjects, 9% from African Americans, and 1% other ( Table 1) . Forty-eight percent of NAF specimens were from premenopausal subjects. Seventy-three percent of specimens came from subjects who had taken birth control pills, and 33% came from subjects who had taken hormone replacement. The number of live births experienced by participants ranged from 0 to 9, and the number of miscarriages from 0 to 5.
Nipple Aspiration. Nipple aspiration was performed as described previously (16) . A trained physician or nurse clinician aspirated nipple fluid noninvasively using a modified breast pump. The nipple was cleansed with alcohol. A warm, moist cloth was placed on the breast after the alcohol evaporated. The cloth was removed after 2 minutes and the subject massaged her breast with both hands while the plunger of the syringe was withdrawn to the 7-mL level or until she experienced discomfort. Aspiration was repeated on the opposite breast, if present. Fluid in the form of droplets (1-200 L) was collected in capillary tubes, and the samples were immediately snap-frozen at Ϫ80°C. If keratin plugs rather than NAF were obtained after suctioning was completed, the plugs were removed with an alcohol swab and suctioning was repeated. Occasionally this procedure was repeated two or three times to remove all of the plugs and, routinely, fluid was then obtained.
Sample Preparation. Samples for two-dimensional PAGE analysis were thawed by breaking the capillary tube directly into denaturing buffer (7 mol/L urea, 2 mol/L thiourea, 1% (w/v) C7 detergent (Sigma-Aldrich, St. Louis, MO), 40 mmol/L Tris), at a ratio of 80 L buffer to 1 L NAF. The proteins were reduced by using 5 mmol/L tri-butylphosphine (TBP) for 1 hour at room temperature and were alkylated with 15 mmol/L iodoacetamide. Pharmalytes isoelectric focusing carrier ampholytes (pH 3-10; Sigma-Aldrich) were added to a final concentration of 1.5%, the samples were centrifuged at 150,000 ϫ g for 1 hour at 4°C in a Beckman TL-100 centrifuge, and the supernatants were kept. Two-Dimensional PAGE Separation. Diluted sample (250 or 400 g) was used to hydrate 11-cm or 24-cm strips, respectively, overnight at room temperature. First-dimension separation was done by focusing the proteins at a total of 80 K volt-hours, with a 6000 V programmable power supply (Proteome Systems Ltd, Boston MA). Second-dimension separation was performed by PAGE on 8-to-18% gradient gel chips (Proteome Systems Ltd), by using Tris-Tricine buffer according to the manufacturer's instructions. Gels were stained overnight by using Colloidal Coomassie Brilliant Blue, destained in 1% acetic acid, and scanned.
Proteomic Analysis. Electronic images of two-dimensional gels were analyzed by using Phoretix 2D-Advance software (Nonlinear Dynamics, Newcastle, United Kingdom). Protein spots were excised and arrayed into 96-well MultiScreen model R5, glass-filled polypropylene plates (Millipore, Bedford, MA) by using 2-mm diameter pins on the GelPix robotic spot excision station (Genetix, Ltd, Hampshire, United Kingdom). Gel plugs were destained in 3ϫ 200 L of 50% (v/v) acetonitrile, 50 mmol/L NH 4 HCO 3 for 15 minutes at room temperature and were dehydrated in 100% acetonitrile for 5 minutes at room temperature. Proteins were digested with 50 L of sequencing grade trypsin (Promega, Madison, WI) at 4 g/mL in 50 mmol/L NH 4 HCO 3 at 37°C for 16 hours. Tryptic peptides were extracted from the gel plugs by shaking for 15 minutes in 50 L of 60% acetonitrile, 1% formic acid, collected into the V-well collection plate under vacuum and concentrated to 5 to 15 L by centrifugal vacuum evaporation. Tryptic peptide samples (0.5 L) were applied to a 96 ϫ 2 Teflon MALDI plate by using a Symbiot IV liquid handling station (Applied Biosystems, Inc., Foster City, CA). The samples were mixed with an equal volume of the matrix solution, 10 mg/mL ␣-cyano-4-hydroxycinnamic acid (Sigma-Aldrich) in 60% acetonitrile, and 0.3% trifluoroacetic acid on an Applied Biosystems Voyager-DE Pro MALDI TOF MS, operated in the positive-ion delayed-extraction reflector mode. Peptides were ionized/desorbed with a 337-nm laser and spectra acquired at 20 kV accelerating potential with optimized settings. The close external calibration method, which used a mixture of standard peptides (Applied Biosystems), provided a mass accuracy of 25 to 50 ppm across the mass range of 600 to 5000 Da. Peptide spectra were automatically processed for baseline correction, noise removal, and peak deisotoping, and were analyzed with Protein Prospector. 4 Search criteria required the match of at least four peptides, with a mass error of less than 50 ppm for a protein assignment. The data were manually reexamined to insure maximum peptide coverage for the identified proteins. When there were isoforms of a protein (i.e., train of spots), all of the spots were analyzed, but only one entry was made in Table 2 .
ELISA Assay. Frozen NAF samples were resuspended by crushing the tube into phosphate-buffered saline (PBS; pH 7.2) containing a protease inhibitor mixture to prevent proteolysis [1:100 dilution of 100ϫ protease inhibitor cocktail: 20 mmol/L 4-(2-aminoethyl)benzenesulfonyl fluoride (AEBSF), 100 g/mL peptstatin A, 10 g/mL leupeptin)]. A constant ratio of 70 L of buffer to 1 L of NAF was maintained in all of the samples to keep the protein concentration comparable between samples, and to insure complete solubility of larger volume samples, because NAF samples are rich in protein (most samples contain between 50 and 300 mg protein/mL) and viscous.
ELISAs were performed by directly adsorbing the NAF samples onto 96-well plates. Five microliters of diluted NAF containing 5 to 20 g of protein were mixed with 45 L of coating buffer (10 mmol/L NaCl, 50 mmol/L NaPO 4 , pH 7.5) in the first well, and subjected to 11ϫ 2-fold serial dilutions into 25 L of coating buffer. The plates were incubated overnight at 4°C to let the proteins adsorb to the plate. Excess solution was decanted, and the plates were blocked with coating buffer containing 0.5% bovine serum albumin for 2 to 4 hours at 4°C. Excess blocking buffer was decanted and 25 L of prediluted primary monoclonal antibody in PBS were added to each well as follows: for apoD (Signet Laboratories, Dedham, MA, cat. no. 9780-02), 1:200 dilution; for GCDFP-15 (Signet, cat. no. 611-13), 1:20 dilution; and for AAG (BIODESIGN, Saco, ME, cat. no. H45190M), 1:100 dilution. The plates were incubated overnight at 4°C. Excess unbound primary antibody was removed, and the plates were washed eight times under running distilled water. Twentyfive microliters of secondary antibody, goat antimouse immunoglobulin ("Linking reagent" no. 4, Signet Labs) at 1:30 dilution in PBS were added to each well, and the plates were incubated for 2 hours at room temperature. Unbound antibody was removed, the plates were washed as above, and were incubated for 2 hours at room temperature in 25 L of mouse antigoat tertiary monoclonal antibody conjugated to horseradish peroxidase ("Labeling reagent" no. 5, Signet Laboratories) at 1:30 dilution in PBS. The plates were washed and developed with 100 L of developing solution [100 mmol/L sodium citrate (pH 5.0), 10 mg/mL o-phenylenediamine dihydrochloride (OPD; Sigma), and 0.006% H 2 O 2 ] for 15 minutes at room temperature. The reaction was stopped by adding 100 L of 2.5 mol/L H 2 SO 4 , and the plates were read in a microtiter plate reader at 490 nm. Antigen concentration in the sample was calculated as the reciprocal of the dilution at the 50% point of the maximum of the linear range of the dilution curve per milligram of total NAF protein.
Protein Determination. Protein concentration was determined by using the bicinchoninic acid assay (BCA, Pierce Biotechnology, Rockford, IL), with 0.1% bovine serum albumin as a standard in 96-well plates.
Statistical Analysis. All of the data are presented as median and range (minimum to maximum). Comparisons between groups (cancer versus no cancer) were conducted by using the Mann-Whitney Rank Sum Test (underlying conditions for parametric tests were not met). Comparisons of more than two groups (e.g., by disease stage-benign, DCIS, invasive cancer) were conducted by using the Kruskal-Wallis One-Way Analysis of Variance on Ranks (underlying conditions for parametric tests were not met). Analyses of categorical data were conducted by using the 2 test. Pearson Product Moment Correlation was used for correlation analyses. In all instances, significance was set at P Ͻ 0.05. All of the data were analyzed with SigmaStat for Windows, Version 2.03S (SPSS, Inc., Chicago, IL).
RESULTS

Subjects
We tested 105 NAF samples, 53 from normal breasts and 52 from breasts with DCIS or invasive cancer. Among the clinical variables compared (age, number of live births, number of miscarriages, ever use of birth control pills or hormone replacement therapy, menopausal status, and race), two variables, age and menopausal status, were related to cancer status (Table 1) . Samples from women with cancer tended to be older than their noncancer counterparts and were postmenopausal more often than their noncancer counterparts.
The Nipple Aspirate Fluid Proteome
To optimize protein identification, two-dimensional PAGE was performed on NAF from one subject without breast cancer on two gels with different pH ranges: 3-10 and 4 -7 ( Fig. 1 ). Spots were excised from each of the two gels and were subjected to Fig. 1 Two-dimensional PAGE analysis of NAF sample. NAF from a subject without breast cancer was processed and separated on two gels with different pH ranges: 3 to 10 and 4 to 7. Protein spots in the middle isoelectric point (pI) range (4.5 to 6.5) were excised from the 4-to-7 gel. Protein spots that were either in the 3-to-4.5 range or in the 6.5-to-10 range were excised from the 3-to-10 gel. (kDa, molecular weight (MW) in thousands.) Note. Results were obtained and analyzed as described in the Materials and Methods section. The entire proteome was analyzed from 2 gels, in which the samples from a normal woman were separated on the first dimension of either a 4 -7 pI strip or a 3-10 pI strip, and the corresponding proteins spots for each protein are listed.
* Gene name, synonyms and protein function were taken from Swiss-Prot (http://us.expasy.org/sprot).
Protein function/comments* Molecular weight search score † % coverage ‡ Secreted. Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2ϩ), Na(ϩ), K(ϩ), fatty acids, hormones, bilirubin, and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood.
4.70Eϩ12 47
Secreted. Alpha feto protein shares considerable homology with serum albumin. Binds copper, nickel, and fatty acids as well as, and bilirubin less well than, serum albumin. Only a small percentage (less than 2%) of the human afp shows estrogen-binding.
6.34Eϩ02 44
Secreted. Appears to function in modulating the activity of the immune system during the acute-phase reaction. 4.75Eϩ07 40 Extracellular. Inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin.
6.21Eϩ00 31 Promotes endocytosis, possesses opsonic properties and influences the mineral phase of bone. Shows affinity for calcium and barium ions.
1.19Eϩ05 22 Secreted. Most important serine protease inhibitor in plasma that regulates the blood coagulation cascade. AT-III inhibits thrombin as well as factors IXa, Xa and X1a. Its inhibitory activity is greatly enhanced in the presence of heparin.
2.18Eϩ04 27
Secreted. APOA1 promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A-I is the major protein component of high density lipoprotein (HDL) in the plasma.
1.71Eϩ07 53
Secreted. A plasma lipoprotein moiety, has a role in lipid absorption, transport and metabolism, and may act as a postprandial satiety signal, an antioxidant and a major factor in the prevention of atherosclerosis.
9.78Eϩ05 39
Secreted. Homodimer. In plasma, also exists as a disulfide-linked heterodimer with apoa2. Occurs in the macromolecular complex with lecithincholesterol acyltransferase. Appears to be able to transport a variety of ligands in a number of different contexts.
5.92Eϩ03 29
Secreted. A major constituent of plasma lipoproteins. ApoE polymorphisms influence serum lipid profile, the pathogenesis of atherosclerosis, the development of neurodegenerative disorders, the pathogenesis and progression of a variety of renal diseases, as well as in the atherosclerotic complications associated with them.
1.09Eϩ03 24
Secreted. Binds to various kinds of negatively charged substances such as heparin, phospholipids, and dextran sulfate. May prevent activation of the intrinsic blood coagulation cascade by binding to phospholipids on the surface of damaged cells.
3.25Eϩ07 47
Implicated in the suppression of cell death. Interacts with the bcl-2 and adenovirus e1b 19-kDa proteins. 1.14Eϩ02 15 BCAR3 represents a putative SH2 domain-containing protein and is partly homologous to the cell division cycle protein CDC48.
2.43Eϩ03 15 Secreted. May play a role in the regulation of the immune system. Seems to play a role as an inhibitor of apoptosis.
1.97Eϩ08 57 Secreted. Not yet clear. It is known to be expressed in a variety of tissues and it seems to be able to bind to cells, membranes and hydrophobic proteins. It has been associated with programmed cell death (apoptosis).
8.22Eϩ04 32
Has homology to acidic c4; rodgers form of c4; c4a anaphylatoxin. 
9.43Eϩ04 18
May be involved in the regulation of gene transcription and chromatin structure. 1.18Eϩ03 14 Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation. Conversion of fibrinogen to fibrin is triggered by thrombin and involves factor xiiia.
1.19Eϩ05 28
The conversion of fibrinogen to fibrin is triggered by thrombin, which cleaves fibrino-peptides A and B from ␣ and ␤ chains, respectively, and thus exposes the amino-terminal polymerization sites responsible for the formation of the soft clot.
7.02Eϩ10 50
Secreted. Expressed in pathological conditions of the mammary gland and in several exocrine tissues such as the lacrimal, salivary, and sweat glands. Induced by prolactin and androgen. Inhibited by estrogen.
2.58Eϩ06 55
Secreted. Combines with free plasma hemoglobin, preventing loss of iron through the kidneys and protecting the kidneys from damage by hemoglobin, while making the hemoglobin accessible to degradative enzymes. Tetramer.
4.12Eϩ04 32
Secreted. Loss of this locus, along with other IgHG loci, leads to agammaglobulinemia. 1.95Eϩ12 48 Secreted. One of two common IgA subclasses, comprising approximately one quarter of total IgA in human sera.
8.16Eϩ03 17 Secreted. Serves to link two monomer units of either IgM or IgA. In the case of IgM, the J chain joined dimmer is a nucleating unit for the IgM pentamer, and in the case of IgA, it induces larger polymers. It also helps to bind these immunoglobulins to secretory component.
6.86Eϩ02 32
Secreted. Believed to play a role in the pathology of infectious and autoimmune diseases. Clonal populations may be found in hematologic malignant diseases.
1.72Eϩ04 59
Secreted. Believed to play a role in the pathology of infectious and autoimmune diseases. Clonal populations may be found in hematologic malignancies.
3.32Eϩ03 43
Thought to aid in nuclear protein transport. 1.10Eϩ02 26 The 67-kDa type II keratins are expressed in terminally differentiating epidermis.
7.65Eϩ04 25 The enzyme cleaves lys-arg and arg-ser bonds. It activates factor xii after its binding to a negatively charged surface. It also releases bradykinin from hmw kininogen and may also play a role in converting prorenin into renin.
2.33Eϩ05 22
May be involved in the regulation of gene expression by covalent modification of histone proteins. The long isoform is a corepressor of estrogen receptor (ER).
2.94ϩ03 14
In muscle, helps to anchor the terminal actin filaments of the myofibril to the membrane, and functions in transmitting tension from the myofibrils to the extracellular matrix. Its function in other tissues is unknown.
1.19ϩ04 31
May play a role in the control of epithelial cell polarity. Seems to help to recruit protein tyrosine kinase 2␤ (PTK2B) to cell matrix adhesions.
9.95ϩ01 14
Belongs to the small GTPase superfamily, Ras family. Interacts with RALBP1 via its effector domain. 6.86ϩ02 32 Secreted. This protein belongs to the lipocalin family and is the specific carrier for retinol (vitamin A alcohol) in the blood. In plasma, the RBPretinol complex interacts with transthyretin.
2.51Eϩ04 40
Secreted. Transferrins are iron binding transport proteins. It is responsible for the transport of iron from sites of absorption and heme degradation to those of storage and utilization. Serum transferrin may also have a further role in stimulating cell proliferation.
1.98Eϩ15 57
Secreted. Thyroid hormone-binding protein. About 40% of plasma transthyretin circulates in a tight protein-protein complex with the plasma retinolbinding protein (rbp).
1.40Eϩ04 72
Secreted. Multifunctional protein found in plasma, ascitic fluid, cerebrospinal fluid, and urine and on the surface of many cell types. In plasma, it carries the vitamin D sterols and prevents polymerization of actin by binding its monomers.
2.19Eϩ12 53
Zinc finger protein, possible transcription factor. 6.53ϩ02 21 Secreted. Stimulates lipid degradation in adipocytes and causes the extensive fat losses associated with some advanced cancers. May bind polyunsaturated fatty acids.
3.14Eϩ08 41 † Accession number and molecular weight search scores were taken from the search results using Protein Prospector. 4 In this program, a molecular weight search score of Ͼ200 is considered significant. ‡ The percentage of the linear protein sequence that is covered by the peptides. It does not reflect the number of hits or the percentage of peptides giving positive identification.
MALDI-TOF analysis. Ninety-one spots were excised from the pH 3-10 gel. Of these, 69 (73%) were identified, yielding 35 different protein identifications. Of the 22 spots that were not identified, 9 spots gave good spectra but no protein identification, and 13 spots resulted in poor spectra. A total of 94 spots were excised from the pH 4 -7 gel. Of these, 53 (56%) spots were identified, yielding 28 different protein identifications. Thirty spots gave no spectra, and 11 spots gave reasonable spectra and no identification. Combining the data from the two gels led to the identification of 41 unique proteins. Positive identification was assigned when there were at least four peptides matched and the percentage linear coverage was over 15%. The list of proteins and detail about their function are presented in Table 2 . Several proteins have been referred to by different names in different studies; these are shown under synonyms in Table 2 .
Selection of Nipple Aspirate Fluid Proteins for ELISA
We performed two-dimensional PAGE on 20 NAF samples (10 from subjects with, and 10 from subjects without breast cancer). Despite variation between different individuals, both in the normal and the diseased samples, we were able to pick 10 protein spots that were visually differentially expressed in cancer patients. These proteins were analyzed by MALDI-TOF MS and were identified as prolactin-induced protein; apoD; ␣1-acid glycoprotein; IgJ; complement C4A (two spots); ␣2 glycoprotein 1 and Ig␣ (2 spots). Three of these proteins (Fig. 2) -spot 1, prolactin-induced protein (GCDFP-15 or BRST2); spot 2, apoD; and spot 3, AAG, which were up-regulated in the NAF from a cancer-containing breast compared with a normal breast from the same woman, as well as from at least two other breasts with cancer-were chosen for further analysis.
ELISA Analysis
Because the preliminary association of these markers with breast cancer was made in a small sample set, the above proteins were next investigated by ELISA in 105 NAF samples (53 from benign breasts and 52 from diseased breasts). The concentration of each of these proteins relative to the total protein concentration in the sample was determined. We used a direct ELISA method on serially diluted NAF extracts. In the absence of commercial kits, this technique is a well-established method to quantitate the level of antigen in a sample. Because we used the Fig. 2 Differential expression of proteins in cancerous versus benign NAF. Matched NAF samples [normal breast (A) and breast with cancer (B)] from the same subject were separated on a 3-to-10, 24-cm immobilized pH gradient (IPG) strip and were separated on an 8-to-18% gel chip. The regions around each spot are shown in the normal versus the cancer sample, and the proteins selected are marked by corresponding arrows. These protein spots were excised and subjected to MALDI-TOF MS analysis, and were identified as prolactin-induced protein (spot 1), apoD (spot 2), and ␣1-acid glycoprotein, respectively (spot 3). (kDa, molecular weight (MW) in thousands.) same concentration of antibody throughout the experiment in all of the wells and we scored the results at the point at which 50% if the antibody was bound, we were able to determine how much each NAF sample needed to be diluted to bind 50% of the antibody. Table 3 shows the correlation of these proteins with the presence of breast cancer and menopausal status. Gross Cystic Disease Fluid Protein 15. ELISAs revealed that median GCDFP-15 expression was 6-fold lower in samples from breasts with cancer than in those without. This lower expression in breasts with cancer than in samples from benign breasts was significantly different, both when considering all subjects (P Ͻ 0.001) and premenopausal subjects (P ϭ 0.011). GCDFP-15 levels were not significantly different in NAF samples from postmenopausal women.
Apolipoprotein D. Apolipoprotein D levels were not associated with the presence of breast cancer, whether considering all subjects or subjects divided by menopausal status.
␣1-Acid Glycoprotein. AAG levels in NAF samples were higher in women with breast cancer, when considering both all subjects (P ϭ 0.001) and premenopausal subjects (P ϭ 0.002). The levels of AAG were not related to breast cancer in postmenopausal women.
GCDFP-15 Levels Are Lowest and AAG Levels Are Highest in Early-Stage Breast Cancer
We wished to determine whether GCDFP-15, apoD, or AAG levels in NAF were related to disease stage (no cancer, DCIS, or invasive breast cancer). We found that the lowest levels of GCDFP-15 (P ϭ 0.003) and the highest levels of AAG (P Ͻ 0.001) were in breasts from women with DCIS (Table 4) . apoD levels were not significantly different based on disease stage. Women with invasive cancer had higher levels of AAG than breasts with benign disease but lower levels than in breasts with DCIS.
Influence of Menopausal Status on apoD and AAG Expression
GCDFP-15, apoD, and AAG expression were measured in both pre-and postmenopausal women. The data presented in Table 5 includes all women, regardless of breast cancer status, as well as controlling for cancer status. GCDFP-15 levels were higher in the breasts of premenopausal women, both overall (P ϭ 0.004) and in breasts without cancer (P ϭ 0.049). apoD expression was not significantly influenced by menopausal status. AAG levels were significantly higher in post-than in premenopausal women, both overall (P ϭ 0.019) and in breasts without cancer (P ϭ 0.009).
DISCUSSION
We believe that proteomic analysis of NAF is more advantageous than proteomic analysis of cells from breast cancer tissue because the protein comparison is less complex. This argument extends to a recent study of the interstitial fluid of breast tumors, in which more than 1000 proteins were identified (17) . Moreover, the secreted proteins in NAF are fully processed, glycosylated, and truncated, and are not influenced by transient protein modifications (such as phosphorylation or changes in redox state, which influence the position of a protein spot on a two-dimensional gel) that affect proteins within the cell. Two-dimensional PAGE was chosen to screen NAF because it provides a convenient and rapid method for protein identification (based on MALDI-TOF MS) that then allows subsequent high-throughput quantitative ELISA studies of the candidate proteins. Although two-dimensional PAGE has limitations in protein separation and sensitivity, it is an excellent choice for initial investiga- Note. Boldface indicates significant differences. tions and, in the present study, posed no problems because of the limited number of proteins in NAF samples. Indeed, the protein makeup of NAF is quite simple, allowing us to identify many of its constituent proteins, as well as easily identify a number of proteins that are differentially expressed. We predict that other proteomic techniques [e.g., isotope-coded affinity tags (ICATs)] will identify additional markers. Nonetheless, the present study strongly supports the idea that NAF will be useful in the diagnosis and prognosis of breast cancer. Proteomic analysis of a limited number of benign and breast cancer NAF samples suggested that there is protein expression variability between women. Nevertheless, proteomic analysis by two-dimensional PAGE identified candidate proteins that are differentially displayed between benign and cancerous samples, and subsequent quantitative analysis with ELISA in a large sample of women showed that the expression of two of the markers (GCDFP-15 and AAG) were, and one (apoD) was not, altered in breast cancer. This underscores the need to validate initial observations with larger sample sets.
Using two-dimensional PAGE and MALDI-TOF MS, we identified 41 distinct proteins in the NAF proteome. We used Colloidal Coomassie Brilliant Blue to identify proteins, and we observed by using parallel gels that commercial silver stains did not appreciably improve protein detection (data not shown). Our attempts to remove albumin and immunoglobulins by using commercial kits also were not very effective. Thus, it is possible that we missed the subset of proteins that were masked by these highly abundant proteins. Additionally, the identification of highly glycosylated proteins may have been limited because, at times, there are very few unglycosylated peptides after trypsin digestion. Thus, although not all NAF proteins were identified by our approach, we think that our approach to defining the NAF proteome provides unique and important information to better characterize this important biological fluid.
A recent study by Varnum et al. (18) analyzed the NAF proteome by using liquid chromatography. More than 60 proteins were identified, many of the proteins the same as those identified in the present study, but a substantial subset of proteins (21 in our study, 35 in the other) are unique to each study. It should be noted that in the Varnum study, pooled NAF samples were used, whereas in our study individual NAF samples were run on two-dimensional gels. Clearly, both studies should be considered when assessing the NAF proteome.
Many of the proteins that we identified in the NAF proteome could potentially be markers of disease, including rasrelated protein; metastasis-associated protein; BCL2, which has been implicated in the suppression of cell death; CD5, which is reported to play a role in the inhibition of apoptosis; retinolbinding protein, which has recently been shown to suppress breast cancer cell survival and has been shown to be downregulated in a subset of breast cancer; clusterin, which has been associated with cell death and apoptosis; and transferin, which has been assigned a role in cell proliferation. (For additional references to these proteins and their functions, see http://us. expasy.org/sprot, and links to related references.) 5 Some of the NAF proteins are known blood proteins. Whether these are blood contaminant proteins or true NAF proteins will require further investigation.
Three proteins, GCDFP-15, AAG, and apoD, were studied in detail. These proteins were chosen because they were all differentially expressed in a small number of cancer versus benign samples, and antibodies were commercially available. Additionally, there was previously existing literature connecting these proteins to breast cancer (19 -21) , confirming the importance of these proteins in disease prediction.
We found that GCDFP-15 levels in NAF from cancerous samples are substantially lower than in samples from breasts without cancer, findings consistent with a report in breast tissue (22) . Petrakis et al. (23) demonstrated that the levels of GC-DFP-15 in NAF are lower in Asian than in non-Asian women and that, under the influence of soy ingestion (24) , GCDFP-15 levels are higher in NAF from normal than from hyperplastic breasts. NAF levels of GCDGP-15 analyzed by one-dimensional PAGE (25) were higher in women without breast cancer. Our findings confirm and extend these findings in a large cohort of women, and demonstrate that this association is limited to premenopausal women.
AAG is an acute phase reactant that is known to play an immunomodulatory role (26) . In patients with chronic myelogenous leukemia in blastic phase, AAG levels reflect pharmacological resistance to chemotherapy (27) . We observed that AAG expression was significantly higher in samples from pre-but not from postmenopausal women with breast cancer. That GC-DFP-15 and AAG were substantially related to breast cancer in pre-but not in postmenopausal women suggests that these proteins may be influenced by ovarian hormones. AAG has been observed to bind tamoxifen, a known estrogen receptor modulator (28) . In postmenopausal women, unopposed estrogen use was associated with modestly lower levels of AAG (29) . This is consistent with our finding of higher levels in postmenopausal women without breast cancer, most of whom have very low levels of circulating estradiol, and with the fact that oral estrogen treatment lowers AAG levels in the blood (30) . Positive immunoreactivity for GCDFP-15 in breast tumors was found to be highly dependent on androgen receptor status, but unrelated to estrogen or progesterone receptor (31) . The identification of biomarkers of breast cancer in premenopausal women is of great importance because, compared with cancers in postmenopausal women, breast cancers that develop in these women are more likely to have a genetic cause, are less likely to respond to hormonal therapy, and are more likely to be aggressive (32) . Alterations in these proteins in premenopausal women, if confirmed, may lead to therapies to treat hormone-unresponsive cancers, those most likely to lead to death.
Apolipoprotein D was first identified as a component of breast cyst fluid and was called GCDFP-24 because of its size (33) . It is present in benign and malignant human breast tissues and is a major protein component in cyst fluid from women with human gross cystic breast disease (34) . A prior report that evaluated NAF by using immunoblotting suggests that levels of apoD are higher in women without than in women with breast cancer (35) . Our analysis of apoD in NAF by ELISA failed to demonstrate a significant relationship to breast cancer.
In summary, we screened cancerous and benign NAF samples by two-dimensional PAGE both to determine proteins present in the NAF proteome and to identify proteins that were differentially expressed between women with and without breast cancer. The proteome as identified by twodimensional PAGE differs from, and is complementary to, a prior report (17) on the proteome with liquid chromatography, because each technique identified both a similar and a unique subset of proteins. No attempt was made in the NAF study that used liquid chromatography to quantitate and compare NAF protein levels in women with and without breast cancer. Validation in a large cohort of subjects by ELISA of the three candidate proteins identified by twodimensional PAGE demonstrated that two of the three were linked to breast cancer, one directly (AAG) and one inversely (GCDFP-15), and that the associations were seen only in premenopausal women. Our findings extend previous observations linking GCDFP-15 and breast cancer, demonstrate a link between AAG and breast cancer, and point to a hormonal influence on the expression of these markers. We believe that a combination of proteomic approaches will result in a comprehensive NAF proteome map. Because of the variability of expression of biomarkers within the population, we suggest that all of the identified proteins be measured in a large number of NAF samples by using ELISAs to further correlate their levels with various disease stages. For proteins for which commercial antibodies are not available, antibodies can be generated against synthetic peptides derived from the protein sequence. In this way a noninvasive predictive breast cancer protein signature will ultimately be developed.
